Sorafinib in combindation with intensive chemotherapy for previously untreated adult FLT3-ITD positive AML: A phase 2 randomised double-blind placebo controlled multi-centre study (ALLG AMLM16)

DOI number 10.58109/1bwn-2c19
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

Andrew Wei (Alfred Hospital)
Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 102 previously untreated FLT3-ITD positive AML patients
  • Sorafenib in combination with intensive chemotherapy versus placebo group
  • Event-Free survival
  • Safety and measures of efficacy
  • Toxicity
  • QoL data
  • Response rates
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)

Chemotherapy
ANZCTR Reference ACTRN12611001112954
Publication(s)
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research
AMLM15
AMLM17 – Phase I